GRFSCIK 1438569

Grifols SA

EDGAR filings

Customers

1 federal agency

Suppliers

0 disclosed

Federal obligations

$1.0M

FY2023 · USAspending.gov

Latest period

Dec 31, 2020

10-K filed 2023-03-07

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Suppliers 2

Companies that disclose GRFS as a major customer, as a share of their own revenue. 0 active, 2 lapsed.

Company	% of their revenue	Est. $ from GRFS	Period	Trend	Status	Source
RIGL RIGEL PHARMACEUTICALS INC	41%	$44.5M	FY 2020-12-31	+33.0pp	Lapsed Last seen 2020-12-31	10-K 2023-03-07
Grifols * * 41% 10-K filed 2023-03-07 Period FY 2020-01-01 to 2020-12-31 (41%)Accession 0001558370-23-003035 7.Revenues Revenues disaggregated by category were as follows (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Product sales: Gross product sales $18,353 $ 12,481 $33,724 $ 22,397 Discounts and allowances (3,379) (2,308) (6,070) (4,170) Product sales, net $ 14,974 $ 10,173 $ 27,654 $ 18,227 Revenues from collaborations: License revenues — — 39,858 4,499 Research and development services and others 1,047 234 4,270 305 Total revenues from collaborations 1,047 234 44,128 4,804 Total revenues $ 16,021 $ 10,407 $ 71,782 $ 23,031 The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues): Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 ASD Healthcare and Oncology Supply 47% 48% 20% 40% McKesson Specialty Care Distribution Corporation 41% 40% 16% 31% Cardinal Healthcare 5% 10% 2% — Grifols 7% — 61% 20% We commenced commercial sale of TAVALISSE in the U.S. in May 2018 after FDA approval in April 2018. 10-Q filed 2020-08-04 Period 3M 2020-04-01 to 2020-06-30 (7%)Accession 0001558370-20-009154 Grifols * 77 % 10-Q filed 2021-05-05 Period 3M 2020-01-01 to 2020-03-31 (77%)Accession 0001558370-21-005903 For the year ended December 31, 2019, our three specialty distributors as well as Aclaris, Grifols, Celgene and Kissei (see Note 2) accounted for 74%, 9%, 8%, 6% and 3% of our total revenues, respectively. 10-K filed 2021-03-02 Period FY 2019-01-01 to 2019-12-31 (8%)Accession 0001558370-21-002254 Grifols 77% 36% 10-Q filed 2020-05-05 Period 3M 2019-01-01 to 2019-03-31 (36%)Accession 0001558370-20-005179
CERS CERUS CORP	18%	$7.1M	FY 2013-12-31		Lapsed Last seen 2013-12-31	10-K 2016-03-09
Grifols * * 18 % 10-K filed 2016-03-09 Period FY 2013-01-01 to 2013-12-31 (18%)Accession 0001193125-16-498617

Federal contracts 1

Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $1.0M in the latest fiscal year shown per agency.

Agency	Obligated	Fiscal year	Awards	Trend	Largest award
Department of Health and Human Services Centers for Disease Control and Prevention	$1.0M	FY 2023	9		75D30123D16112
VACCINES FOR CHILDREN Award 75D30123D16112 on USAspending.gov ↗ Largest of 9 awards in FY2023: $914.5K obligated

Alerts are coming

Get an email when GRFS's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.